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Abstract
We have explored a method to convert a muraymycin biosynthetic intermediate 3 to an anticancer 
drug lead 2 for in vivo and thorough preclinical studies. Cu(OAc)2 forms a stable complex with 
the amide 4 and it prevents electrophilic reactions at the 2-((3-aminopropyl)amino)acetamide 
moiety. Under the present conditions, the desired 5”-primary amine was selectively protected with 
(Boc)2O to yield 6. The intermediate 6 was converted to 2 in two steps with 90% yield.
Graphical Abstract
N-linked glycans play essential roles in many biological processes. Aberrant protein 
glycosylation is frequently observed in cancer cells. The integral membrane enzyme, N-
acetylglucosaminephosphotransferase 1 (DPAGT1), plays a central role in N-linked 
glycoprotein biosynthesis, catalyzing the first step in the dolichol-linked oligosaccharide 
pathway. Certain cancer cells require an increase in N-linked glycosylation for their 
progression, thus, selective DPAGT1 inhibitors have therapeutic potential.1 The only 
inhibitors of DPAGT1 that have been reported to date are the antibiotic tunicamycin and its 
derivatives. Tunicamycins have been useful experimental tools to interrogate N-linked 
glycosylation and to examine the effects on protein folding.2 Tunicamycins inhibit growth 
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across a wide range of mammalian cell lines in a non-selective fashion.1a In addition, 
physicochemical and biological properties of tunicamycins (e.g. water-solubility and narrow 
therapeutic window) are far from ideal as leads for the development of preclinical drugs. 
Therefore, new types of inhibitors are required. We have recently identified a strong 
DPAGT1 inhibitor, aminouridyl phenoxypiperidinbenzyl butanamide (APPB, 1), by 
screening of an aminoribosyl-uridine library generated based on muraymycin (Figure 1).
1a,1b
 APPB selectively inhibits growth of solid tumors (e.g. KB, LoVo, SK-OV-3, MDA-
MB-432S, HCT116, Panc-1, and AsPC-1) at low μM concentrations but does not inhibit 
growth of healthy cells at these same concentrations.1a APPB displayed a remarkably 
selective cytotoxicity (e.g. IC50 pancreatic cancer cells/ IC50 healthy cells: >1/100), 
metabolic stability (t1/2 >60 min.), and water solubility (~75 mg/mL for HCl salt). Thus, 
pharmacological studies of APPB and its related analogs using appropriate animal models 
are a focus of our continuing research efforts. APPB is a total synthetic product that is not 
feasible to access from reported natural products or muraymycin biosynthetic intermediates.
3
 Based on our structure-activity relationship studies of APPB, it was realized that a urea 
analogue, aminouridyl phenoxypiperidinbenzyl urea (APPU, 2 in Figure 1) shows equal 
biological activity to APPB without reducing the favorable physicochemical properties. 
Importantly, APPU has the potential to be synthesized from a biosynthetic intermediate of 
muraymycin (3) whose structure corresponds to de-N-methyl FR-900463.1d,4 Intermediate 3 
can potentially be produced at large-scale by the disruption of the mur30 gene in the 
muraymycin-producing Streptomyces sp. NRRL 30471 (Figure 2).3 However, no synthetic 
method has been developed to convert the non-biologically active intermediate 3 to a 
pharmaceutically interesting product.5
In a semi-synthetic approach with 3, the most challenging transformation is the selective 
carbamation (temporary protection) of the primary amine (C5”-position) of the aminoribose 
moiety that allows functionalization at the other primary amine (C3”’-position). In this 
article, we report a semi-synthesis of APPU (2) from 3 by exploring transition metals that 
temporarily protect the 2-((3-aminopropyl)amino)acetamide system to achieve selective 
carbamation at the C5”-amine (Scheme 1).
We have previously demonstrated amidation of protecting group free-amino acid derivatives 
with NH4Cl (excess), EDCI, glyceroacetonide-Oxyma, and NaHCO3 in water media.1d,6 
Under the same condition, 37 was converted to the corresponding amide 4 in over 95% yield 
(Scheme 1). The amide 4 was examined in transition metal-mediated selective Boc-
protection under aq NaOH in a mixture of DMF, MeOH, and H2O. Because of the strong 
coordination aptitude of group 4 elements to diamines, we screened Cu, Ni, Zn, V, Co, and 
Fe salts for selectively synthesizing the mono-Boc-protected triamine 7 in excellent yield. 
The transition-metal salts tested, selectivity of mono-/di-Boc (7/8), and isolation yield for 7 
are summarized in Table 1. Reactions of 4 with a majority of the metal salts in Table 1 
caused precipitation in a single solvent system (e.g. MeOH, H2O, or DMF); all reactions 
were carried out in a mixture of DMF-MeOH-H2O (1/1/1). Without addition of a transition 
metal salt, Boc-protection of 4 furnished a 1:1 mixture of 7 and 8 (entry 14).8 Boc-protection 
reactions in the presence of Zn salts, CoCl2, or Fe species provided 1:1 ratio of (7/8) with 
<50% isolation yield for 7 (entries 9–13). VCl3-mediated Boc-protection of 4 exhibited 7/8 
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selectivity of 4:1 and 7 was isolated in 40% yield after 12 h (entry 8). All Ni species tested 
gave rise to the desired mono-Boc product 7 in 85% yield with >19:1 (entries 5–7). Selective 
Boc-protection reactions mediated via the Cu species provided the only desired product 7 in 
10–95% yield (entries 1–4). CuSO4- and CuBr2-mediated reactions did not progress toward 
completion even after 12 h (entries 1 and 3). On the other hand, selective Boc-protection 
performed with Cu(OAc)2 or CuCl2 provided 7 in 90–95% yield (entries 2 and 4). 
Kinetically, the Cu(OAc)2-mediated reaction is more favorable to the production of 7 than 
that with CuCl2; the reaction was completed in 1 h with Cu(OAc)2 (vs. 5 h with CuCl2). It 
may be attributed to the stronger coordination ability of CuCl2 to the C5”-amine, slowing 
down the electrophilic reaction with (Boc)2O. This hypothesis was proven correct by the 
successful reaction in the strictly controlled condition (1.0 equiv of CuCl2); 7 was 
synthesized in >90% in 1 h. We also examined selective Cbz-protection of 4 via the 
Cu(OAc)2-mediated condition developed in Table 1 (Scheme 2). In both cases (CbzCl and 
CbzOSu), 4 could be converted to the desired mono-Cbz protected product 9 in 95% without 
formation of di-Cbz by-product 10.
To obtain insight into mechanisms of the Cu-mediated selective Boc protection, we 
performed NMR studies for the Cu-4 complexes. Unfortunately, all Cu salts in Table 1 
showed poor solubility in the complexation with 4 in conventional deuterated solvents (i.e. 
D2O, d6- DMSO, d6-acetone, and CD3OD). Thus, we synthesized two model compounds 11 
and 12, and a mixture of 11 and 12 were applied to investigate complexation with the Cu-
salts in solution. Complexation of 11 and 12 with CuCl2 resulted in less precipitate and 
higher-resolution NMR. 1H-NMR of a 1:1:1 mixture of 11, 12, and CuCl2 in D2O revealed 
that all carbon protons of the 2-((3-aminopropyl)amino)acetamide moiety of 11 are shifted 
to downfield; Δδ values were +0.73, +0.50, +0.26, and +0.05 for C2-H, C1’−2H, C2’−2H, 
and C3’−2H, respectively. In 13C-NMR of 11-CuCl complex, no chemical shifts were 
observed due to the complexation of 11 with CuCl2. Although participation of the carbonyl 
oxygen in 11-CuCl complex cannot be determined by these NMR experiments, coordination 
of the Cu-amide derivatives have previously been reported; based on X-ray and 
spectroscopic studies, the carbonyl groups of the primary amides are responsible for the 
formation of the stable Cu(II) complexes.9 In our NMR analyses, in the presence of CuCl2, 
the C5–2H in the aminoribose derivative 12 were not shifted (Δδ = 0), thus these data in 
solution-state may support that the C5”-amino group in 4 remains reactive in electrophilic 
reactions. Considering these facts, we speculate that the coordination geometries around the 
Cu(II) ion and 2-((3-aminopropyl)amino)acetamide moiety (highlighted in red) of 4 are as 
shown in 4-CuCl complex in Figure 3.
Finally, we examined the urea-formation of the mono-Boc protected molecule 9 with the 
imidazole-carboxamide derivative 13 and deprotection to synthesize APPU (2). The 
coupling reaction between 9 and 13 was best performed in a mixed solvent system of DMF-
CH2Cl2 (1/1) in the presence of Et3N to furnish the urea 14 in 90% yield. Deprotection of 14 
with 30% TFA provided APPU•TFA (2-TFA). Purification of 2-TFA salt was performed by 
ion-exchange column (DOWEX 50Wx4, H+) to afford 2 in quantitative yield. The synthetic 
APPU (2) in Scheme 3 was determined by 1H- and 13C-NMR, MS, and HPLC to be 
identical to a sample previously synthesized via a total synthesis (see SI)1d.
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In conclusion, we have established the semi-synthesis of an anticancer agent, APPU (2), 
from the muraymycin biosynthetic intermediate 3. It was demonstrated that the 2-((3-
aminopropyl)amino)acetamide moiety in the amide derivative 4 forms complexes with Cu 
species either in water or water-containing organic solvent systems. Such complexes can 
serve as protection of the primary amine at the C3”-position in 4, allowing us to perform 
selective carbamate- formation reactions of the primary amine at C5”-position. Synthetic 
pathways illustrated in Scheme 1 and 3 warrant a wide range of application of the 
biosynthetic intermediate 3 for development of novel agents to cure human diseases (i.e. 
infectious and oncology fields). We are currently studying disruption of the mur30 gene of 
Streptomyces sp. NRRL 30471 to improve production of 3 (Figure 2).10 Practicality of 
isolation and purification of 3 with the genetically modified Streptomyces sp. and a larger 
scale semi-synthesis of a DPAGT1 inhibitor with strong anticancer activity will be reported 
elsewhere.
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Figure 1. 
Structures of Anticancer DPAGT1 Inhibitors, APPB (1), APPU (2), and tunicamycin.
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Figure 2. 
Biosynthesis of Muraymycins in Streptomyces sp. NRRL30471.
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Figure 3. 
Plausible 4-CuCl Complex Proposed Based on NMR Analyses.
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Scheme 1. 
Semi-synthetic Strategy of 1 from 2.
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Scheme 2. 
Selective Cbz-protection of 4.
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Scheme 3. 
Synthesis of APPU (1) from 9.
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Table 1.
Selective Boc-protection of 4.a
Entry MLx Time (h) Selectivity (7 : 8)c Yield for 7 (%)d
1 CuSO4 12 1 : 0 20
2 Cu(OAc)2 12(1)b 1 : 0 95
3 CuBr2 12 1 : 0 10
4 CuCl2 12(5)b,e 1 : 0 90
5 NiCl2•6H2O 12(5)b >19 : 1 85
6 Ni(OAc)2•nH2O 12(5)b >19 : 1 85
7 Ni(NO3)2•6H2O 12(5)b >19 : 1 85
8 VCl3 12 4 : 1 40
9 Zn(NO3)2•6H2O 12(3)b 1 : 1 45
10 ZnCl2 12(3)b 1 : 1 40
11 CoCl2 12(3)b 1 : 1 45
12 FeSO4•H2O 12(3)b 1 : 1 40
13 FeCl3•6H2O 12(3)b 1 : 1 40
14 - 12(1)b 1 : 1 35
a
Reaction condition: 3 (1.0 equiv), MLx (3.0 equiv), and NaOH (1N, 4.0 equiv) in DMF-MeOH-H2O (1/1/1, 0.05M), after 30 min. (Boc)2O (2.5 
equiv)
b
time in the parenthesis: time required for the reaction to be completed
cSelectivity was determined via HPLC analysis for the reaction mixtures after 12h
d
Isolated yield
e
the same reaction with CuCl2 (1.0 equiv) provided 6 in >90 yield in 1 h.
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